Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 2/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | CHKA | P35790 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5282620 | 0.85 | ADRA2A (0.35) | NOS2ADRA2AADRA2BADRA2CNOS1 | |
| SCHEMBL5281677 | 0.85 | TSHR (0.40) | ADRA2AADRA2BADRA2CCHKA | |
| SCHEMBL22250113 | 0.79 | RAPGEF4 (0.36) | RAPGEF4CHKA | |
| SCHEMBL10625457 | 0.78 | NOS2 (0.37) | RAPGEF4NOS2ADRA2AADRA2BADRA2C | |
| SCHEMBL10345008 | 0.76 | ADRA2A (0.38) | ADRA2AADRA2BADRA2CCHKA | |
| SCHEMBL10345192 | 0.76 | CA12 (0.46) | ADRA2AADRA2BADRA2C | |
| SCHEMBL28096130 | 0.76 | P2RX1 (0.38) | RAPGEF4 | |
| SCHEMBL28095786 | 0.73 | TACR1 (0.37) | NOS2NOS1 | |
| SCHEMBL24687899 | 0.71 | ALDH1A1 (0.47) | ADRA2AADRA2BADRA2C | |
| SCHEMBL8212504 | 0.70 | TAAR1 (0.65) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006103342-A9 | INDANYL-PIPERAZINE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SERVIER LAB (FR) | 2007-10-25 | — | — | WO | disclosed |
| US-20060223830-A1 | Indanyl-piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2006-10-05 | — | — | US | disclosed |
| WO-2006103342-A2 | INDANYL-PIPERAZINE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223830-A1 | Indanyl-piperazine compounds | HTR4, NR4A1, NR4A3 | RAPGEF4 2376/4885NOS2 1230/4885ADRA2A 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.